Swiss biopharmaceutical company Bioeq AG and India-based life-sciences company Zydus Lifesciences Limited announced on Tuesday that Zydus's wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, has formed a strategic partnership with Bioeq.

The agreement covers the licensing, supply, and commercialisation of Bioeq's Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO, an interchangeable biosimilar of Lucentis (ranibizumab) for the US market. The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for NUFYMCO.

Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO in the US market.